Eli Lilly and Company

An Expanded Access Program for AM0010 (Pegilodecakin)

Official Title: 
An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection
Brief Summary: 
This is an Expanded Access Program (EAP) available to patients who have advanced cancers, who have failed or progressed on standard of care systemic therapy and do not qualify for ongoing clinical trials.
Temporarily not available
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer

Biological: AM0010
Other Name: LY3500518
Other Name: Pegilodecakin

Eligibility Criteria: 

- Patient is NOT eligible for other AM0010 clinical trials currently open in the region

- Patient is in urgent need of therapy who fail to meet eligibility criteria for other clinical trials related to AM0010 (PEG-IL-10) can be considered for enrollment into this Expanded Access Program.

- Patient has advanced cancer in indications where preliminary anti-tumor efficacy of AM0010 has been demonstrated or where AM0010 mediated immune activation is likely to benefit the patient.

- Patient has failed or progressed on standard of care (SOC) systemic therapy

- Patient is refusing SOC therapy

Eligibility Gender: 
Eligibility Age: 
Minimum: 18 Years

Contact Lilly at 1-800-LillyRx (1-800-545-5979)
Study Director
Eli Lilly and Company

Eli Lilly and Company
ARMO BioSciences
EA Number: 
MeSH Terms: 
Carcinoma, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Pancreatic Neoplasms
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.